Please find enclosed herewith Investors Presentation for Q4 & FY 2025-26
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alivus Life Sciences (formerly Glenmark Life Sciences) reported FY26 revenue of ₹25,518 Mn, up 6.9% YoY, with EBITDA of ₹8,577 Mn growing 19.6% and PAT of ₹5,645 Mn up 16.2%. Q4FY26 revenue was ₹6,891 Mn (6.1% YoY) with EBITDA margin at 34.4% and PAT margin at 23.6%, both up YoY. Gross margins improved 420 bps YoY to 60.7% in Q4, driven by new launches, product mix and operational efficiency. EBITDA margin for FY26 was 33.6%, up 360 bps from FY25. The company generated strong free cash flow of ₹2,590 Mn, ending with cash of ₹7,824 Mn. The CDMO business delivered an 18% YoY turnaround in H2 FY26. Non-GPL business now contributes 71% of revenue, growing 13% YoY. Under Nirma's ownership since 2024, the company has shifted from capital-constrained legacy operations to a standalone growth agenda with increased capex (₹5,400 Mn planned for FY27) and a greenfield Solapur expansion targeting 2,690 KL capacity by FY28.
Margin expansion to 33.6% with EBITDA growing nearly 20% signals structural operational improvement, not just cyclical recovery. Management's FY27 guidance of high single-digit revenue growth and margins above 30% indicates continued momentum, supported by CDMO scale-up, new product launches, and a healthier business mix (71% non-GPL). The strong cash position of ₹7,824 Mn provides a solid buffer for growth capex and potential inorganic moves.